Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00497991 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
A Phase 1 study of Myeloid Leukemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 10
- Study locations
NCT00497991 is a Phase 1 study of Myeloid Leukemia that has completed, run by AstraZeneca. The registered enrollment target is 65 participants, roughly in line with the 70-participant average among 6 other Myeloid Leukemia trials with a reported enrollment target. The trial reports 10 study locations across 3 states.
The verdict
NCT00497991, a Phase 1 study of Myeloid Leukemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to assess safety and tolerability of multiple ascending doses of AZD1152 and to assess effect of AZD1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia.
Conditions Studied
Interventions
- DRUG AZD1152
Study Locations (10)
Other
- Research Site - Angers
- Research Site - Grenoble
- Research Site - Le Chesnay
- Research Site - Bologna
- Research Site - Roma
- Research Site - Amsterdam
- Research Site - Nijmegen
- Research Site - Rotterdam
New York
- Research Site - New York
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00497991
The ClinicalTrials.gov registry entry for NCT00497991 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 70-participant average among 6 other Myeloid Leukemia trials with a reported enrollment target. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which AZD1152 is the first listed.
NCT00497991 reports 10 study locations spanning 3 distinct geographic areas - top geographies include Other, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT00497991 about?
NCT00497991 is a clinical study titled "Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia". The purpose of this study is to assess safety and tolerability of multiple ascending doses of AZD1152 and to assess effect of AZD1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia.
What is the current status of trial NCT00497991?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2006-05. Estimated completion is 2010-04.
What conditions does trial NCT00497991 study?
This clinical trial studies the following conditions: Myeloid Leukemia.
What interventions are being tested in trial NCT00497991?
The interventions under investigation include: AZD1152 (DRUG).
Who is sponsoring clinical trial NCT00497991?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00497991 being conducted?
This trial has 10 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RECRUITING · Phase 1
-
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
RECRUITING · Phase 2
-
Integrated Actionable Aging Assessment for Cancer Patients Pilot
ACTIVE NOT RECRUITING · NA
-
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.